Protective mechanism and clinical application of SGLT2 inhibitors in patients with type 2 diabetes mellitus complicated with abnormal liver function

Yunhui Zhao

doi:10.62051/ijphmr.v1n1.05

Authors

Yunhui Zhao

DOI:

https://doi.org/10.62051/ijphmr.v1n1.05

Keywords:

SGLT2 inhibitors, Type 2 diabetes, Abnormal liver function, Protective mechanism, Clinical application

Abstract

Type 2 diabetes (T2DM) patients with abnormal liver function will further aggravate the complexity of the disease and affect the quality of life of patients. Sodium-glucose cotransporter protein 2 (SGLT2) inhibitors are novel hypoglycemic agents that may produce hepatoprotective effects in patients with T2DM combined with hepatic function abnormalities by improving hyperglycemic toxicity, regulating lipid metabolism, decreasing visceral adiposity, anti-inflammatory, antioxidant and other possible mechanisms. However, the exact mechanism has not been clarified and further studies are still needed. In this article, we reviewed the possible mechanisms of hepatoprotective effects of SGLT2i on patients with T2DM combined with abnormal liver function and the progress of clinical application, in order to providing reference for the rational application of SGLT2i.

References

Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus [J]. Clinical drug investigation, 2019, 39(7): 631-641.

Li B, Wang Y, Ye Z, Yang H, Cui X, Wang Z, Liu L. Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials [J]. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2018, 21(1): 222-235.

Bica I C, Stoica R A, Salmen T, Janež A, Volčanšek Š, Popovic D, Muzurovic E, Rizzo M, Stoian A P. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials [J]. Medicina (Kaunas, Lithuania), 2023, 59(6).

Wong C, Yaow C Y L, Ng C H, Chin Y H, Low Y F, Lim A Y L, Muthiah M D, Khoo C M. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis [J]. Frontiers in endocrinology, 2020, 11: 609135.

Schernthaner G, Lavalle-González F J, Davidson J A, Jodon H, Vijapurkar U, Qiu R, Canovatchel W. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes [J]. Postgraduate medicine, 2016, 128(8): 725-730.

Lee P C H, Gu Y, Yeung M Y, Fong C H Y, Woo Y C, Chow W S, Tan K, Lam K S L. Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study [J]. Diabetes therapy: research, treatment and education of diabetes and related disorders, 2018, 9(1): 285-295.

Kinoshita T, Shimoda M, Sanada J, Fushimi Y, Hirata Y, Irie S, Obata A, Kimura T, Hirukawa H, Kohara K, Tatsumi F, Kamei S, Nakanishi S, Mune T, Kaku K, Kaneto H. There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study [J]. Diabetes therapy: research, treatment and education of diabetes and related disorders, 2018, 9(4): 1569-1580.

Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde A M, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin [J]. The Journal of clinical endocrinology and metabolism, 2012, 97(3): 1020-1031.

Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, Yamaguchi S, Kanno K, Ogawa Y. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction [J]. PloS one, 2016, 11(3): e0151511.

Yanai H, Hakoshima M, Katsuyama H. The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors [J]. Journal of clinical medicine research, 2019, 11(11): 769-772.

Colosimo S, Ravaioli F, Petroni M L, Brodosi L, Marchignoli F, Barbanti F A, Sasdelli A S, Marchesini G, Pironi L. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis [J]. Liver international: official journal of the International Association for the Study of the Liver, 2021, 41(4): 731-742.

Bonnet F, Scheen A J. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease [J]. Diabetes & metabolism, 2018, 44(6): 457-464.

WU Jiaojiao. Effect of SGLT-2 inhibitors on visceral fat area in patients with T2DM [D], 2022

Koutoukidis D A, Astbury N M, Tudor K E, Morris E, Henry J A, Noreik M, Jebb S A, Aveyard P. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis [J]. JAMA internal medicine, 2019, 179(9): 1262-1271.

Lee P C, Ganguly S, Goh S Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms [J]. Obesity reviews: an official journal of the International Association for the Study of Obesity, 2018, 19(12): 1630-1641.

Nishimiya N, Tajima K, Imajo K, Kameda A, Yoshida E, Togashi Y, Aoki K, Inoue T, Nakajima A, Utsunomiya D, Terauchi Y. Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease [J]. Internal medicine (Tokyo, Japan), 2021, 60(21): 3391-3399.

Ogawa Y, Nakahara T, Ando Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Murakami E, Kawaoka T, Miki D, Yamauchi M, Tsuge M, Imamura M, Oka S. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes [J]. European journal of gastroenterology & hepatology, 2023, 35(9): 989-996.

Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl U C, Woerle H J. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients [J]. The Journal of clinical investigation, 2014, 124(2): 499-508.

Leiter L A, Forst T, Polidori D, Balis D A, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes [J]. Diabetes & metabolism, 2016, 42(1): 25-32.

Tyagi K, Madan S, Prakash Bhatt S, Ansari I A, Dutta K, Misra A. Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus and moderate to severe hepatic fibrosis: A retrospective study [J]. Clinical nutrition ESPEN, 2023, 57: 305-310.

Li Xiaojing, SUN Yuanlong, ZHANG Binbin, Mei Zubing, FENG Qin, HU Yiyang. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease [J]. Journal of Hepatobiliary Diseases, 2020, 36(10): 2241-2247.

Bañares J, Manzano-Nuñez R, Prió A, Rivera-Esteban J, Camps-Relats L, Villarejo A, Ruiz-Ortega L, Pons M, Ciudin A, Salcedo M T, Vargas V, Genescà J, Pericàs J M. Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study [J]. Frontiers in endocrinology, 2022, 13: 945626.

Chen Dongmei, Wei Dong. Glucose-sodium cotransporter-2 inhibitors in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis Journal of Integrated Traditional Chinese and Western Medicine Hepatology, 2021, 31(12): 1100-1104.

Seko Y, Sumida Y, Sasaki K, Itoh Y, Iijima H, Hashimoto T, Ishii S, Inagaki N. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials [J]. Journal of gastroenterology, 2018, 53(1): 140-151.

Gautam A, Agrawal P K, Doneria J, Nigam A. Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease [J]. The Journal of the Association of Physicians of India, 2018, 66(8): 62-66.

Inoue M, Hayashi A, Taguchi T, Arai R, Sasaki S, Takano K, Inoue Y, Shichiri M. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease [J]. Journal of diabetes investigation, 2019, 10(4): 1004-1011.

Xiong W, Xiao M Y, Zhang M, Chang F. Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials [J]. Medicine, 2016, 95(48): e5473.

Latva-Rasku A, Honka M J, Kullberg J, Mononen N, Lehtimäki T, Saltevo J, Kirjavainen A K, Saunavaara V, Iozzo P, Johansson L, Oscarsson J, Hannukainen J C, Nuutila P. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients [J]. Diabetes care, 2019, 42(5): 931-937.

Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, Leerapun A, Phrommintikul A, Buranapin S, Chattipakorn N, Thongsawat S. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease [J]. Journal of gastroenterology and hepatology, 2021, 36(10): 2952-2959.

Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin [J]. Cardiovascular diabetology, 2017, 16(1): 149.

Euh W, Lim S, Kim J W. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease [J]. Frontiers in endocrinology, 2021, 12: 613389.

Horibe K, Morino K, Miyazawa I, Tanaka-Mizuno S, Kondo K, Sato D, Ohashi N, Ida S, Yanagimachi T, Yoshimura M, Itoh R, Murata K, Miura K, Arima H, Fujita Y, Ugi S, Maegawa H. Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial [J]. Diabetes research and clinical practice, 2022, 186: 109781.

Pan Juan, Wang Qi, Zhang Yan. Efficacy and safety of dagaglizin combined with metformin in the treatment of type 2 diabetes mellitus with non-alcoholic fatty liver disease [J]. Guizhou medicine, 2023, 47(03): 406-407.

Nie Yan, Ding Hongcheng, Li Yanli, LIAO Chunfen, Julie. Clinical efficacy of daglipzin and metformin in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease [J]. Jiangsu Medicine, 2021, 47(03): 286-289. (in Chinese)

Kuchay M S, Krishan S, Mishra S K, Farooqui K J, Singh M K, Wasir J S, Bansal B, Kaur P, Jevalikar G, Gill H K, Choudhary N S, Mithal A. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) [J]. Diabetes care, 2018, 41(8): 1801-1808.

Hüttl M, Markova I, Miklankova D, Zapletalova I, Poruba M, Haluzik M, Vaněčkova I, Malinska H. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia [J]. International journal of molecular sciences, 2021, 22(21).

Kahl S, Gancheva S, Straßburger K, Herder C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch M, Kantartzis K, Kupriyanova Y, Markgraf D, Van Gemert T, Knebel B, Wolkersdorfer M F, Kuss O, Hwang J H, Bornstein S R, Kasperk C, Stefan N, Pfeiffer A, Birkenfeld A L, Roden M. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial [J]. Diabetes care, 2020, 43(2): 298-305.

Pokharel A, Kc S, Thapa P, Karki N, Shrestha R, Jaishi B, Paudel M S. The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease [J]. Cureus, 2021, 13(7): e16687.

Chehrehgosha H, Sohrabi M R, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, Ajdarkosh H, Khoonsari M, Fallah A E, Khamseh M E. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial [J]. Diabetes therapy: research, treatment and education of diabetes and related disorders, 2021, 12(3): 843-861.

Tabuchi H, Maegawa H, Tobe K, Nakamura I, Uno S. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results) [J]. Endocrine journal, 2019, 66(1): 31-41.

Nakamura I, Maegawa H, Tobe K, Uno S. Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study [J]. Advances in therapy, 2021, 38(8): 4599-4601.

Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, Nakajima T, Imajo K, Tanaka K, Kubotsu Y, Isoda H, Oeda S, Kurai O, Yoneda M, Ono M, Kitajima Y, Tajiri R, Takamori A, Kawaguchi A, Aishima S, Kage M, Nakajima A, Eguchi Y, Anzai K. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD [J]. Hepatology communications, 2022, 6(1): 120-132.

Tobe K, Maegawa H, Nakamura I, Uno S. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM) [J]. Endocrine journal, 2021, 68(8): 905-918.

Alkabbani W, Gamble J M. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date [J]. Drug design, development and therapy, 2021, 15: 3057-3069.

Shen Yang, Lin Jinjun, Zhao Yu Effect of dapagliflozin on liver function in patients with type 2 diabetes mellitus and fatty liver [J]. China Practical Medicine, 2020, 15(25): 130-132

Gallo S, Calle R A, Terra S G, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials [J]. Diabetes therapy: research, treatment and education of diabetes and related disorders, 2020, 11(8): 1849-1860.

[Kasahara-Ito N, Fukase H, Ogama Y, Saito T, Ohba Y, Shimada S, Takano Y, Ichihara T, Terao K, Nakamichi N, Kumagai Y, Ikeda S. Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects [J]. Drug research, 2017, 67(6): 349-357.

Sahasrabudhe V, Terra S G, Hickman A, Saur D, Raje S, Shi H, Matschke K, Zhou S, Cutler D L. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment [J]. Clinical therapeutics, 2018, 40(10): 1701-1710.

Yamada H, Ohira H, Ikegami F, Nakamura K, Takahashi A, Abe K, Inano A, Shimada S, Miyata K, Saito T, Ohba Y, Terao K, Ohnishi A. Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor [J]. Drug research, 2020, 70(9): 401-409.

Seino H. Correction to: Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial [J]. Diabetes therapy: research, treatment and education of diabetes and related disorders, 2021, 12(10): 2807-2811.

Shao S C, Kuo L T, Chien R N, Hung M J, Lai E C. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews [J]. BMJ open diabetes research & care, 2020, 8(2).